Eli Lilly & CO Form 4 insider transactions

Mary Lynne Hedley, a director at Eli Lilly, acquired 13 shares of common stock through a deferral plan, while also holding 1,449 shares indirectly through a trust.

Director Juan R. Luciano acquired 20 shares of Eli Lilly common stock through a deferral plan, as reported in a recent SEC filing.

Kimberly H. Johnson, a director at Eli Lilly & Co, acquired 13 shares of common stock through a deferral plan.

Director Ralph Alvarez acquired 16 shares of Eli Lilly common stock through a deferral plan, as reported in a recent SEC filing.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold over 100,000 shares of common stock in a series of transactions on February 16, 2024.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., has sold a portion of its holdings in multiple transactions on February 15, 2024.

Anne E. White, an Executive Vice President at Eli Lilly, reported the acquisition of common stock and restricted stock units.

Executive Vice President of Human Resources and Diversity at Eli Lilly, Eric Dozier, reported a gift of 408 shares and the acquisition of 1,336 shares of common stock.

Eli Lilly executive Jacob Van Naarden reported the acquisition and disposal of company stock and restricted stock units on February 12, 2024.

Eli Lilly's SVP, Finance, & CAO, Donald A. Zakrowski, reported acquiring 1,254 shares of common stock and holding 1,708 shares indirectly through a 401(k).

Anat Ashkenazi, EVP & CFO of Eli Lilly, reported acquiring 4,210 shares of common stock and 4,904 restricted stock units, while also disposing of 42,330 shares held indirectly through a 401(k).

Daniel Skovronsky, an executive at Eli Lilly, reported acquiring shares and restricted stock units in the company.

Eli Lilly's Executive Vice President, General Counsel, and Secretary, Anat Hakim, acquired 5,815 shares of common stock and 4,904 restricted stock units on February 12, 2024.

Eli Lilly CEO David Ricks acquired shares and restricted stock units, while also reporting changes in his indirect holdings.

Eli Lilly's EVP and President of International, Ilya Yuffa, acquired 4,790 shares of common stock and 3,269 restricted stock units on February 12, 2024.

EVP & President of Manufacturing Operations at Eli Lilly, Edgardo Hernandez, reports acquisition of common stock and restricted stock units, as well as a disposition of common stock.

Executive Vice President of Eli Lilly, Patrik Jonsson, reports the acquisition and disposal of company stock and restricted stock units.

Eli Lilly's Executive Vice President and Chief Information and Digital Officer, Diogo Rau, acquired 3,269 restricted stock units on February 12, 2024.

An Eli Lilly executive, Alonzo Weems, acquired 951 shares of common stock and 980 restricted stock units on February 12, 2024.

Executive Vice President of Global Quality at Eli Lilly, Johna Norton, reported the acquisition of 1,668 shares of common stock and 1,308 restricted stock units, along with the disposal of 402 shares.

Eli Lilly CEO David Ricks transferred 956 shares of company stock to a spousal lifetime access trust on February 8, 2024.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., has sold a portion of its holdings in multiple transactions on February 9, 2024.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold 8,743 shares of common stock at a weighted average price of $740.059 per share.

Anat Hakim, an executive at Eli Lilly, reported the acquisition of 4,442 shares of common stock through the vesting of restricted stock units and the disposal of 1,967 shares to cover tax obligations.

Eli Lilly's EVP and President of International, Ilya Yuffa, reported the acquisition of 3,702 shares and the disposal of 1,664 shares of common stock on February 1, 2024.

Eli Lilly CEO David Ricks executed stock transactions involving the acquisition of shares through restricted stock units and the disposition of shares to cover tax obligations.

Eli Lilly executive Patrik Jonsson reported the acquisition and disposal of company stock and restricted stock units on February 1, 2024.

Eli Lilly executive Daniel Skovronsky reported the acquisition of 9,941 shares through the vesting of restricted stock units and the disposition of 4,434 shares to cover tax obligations.

Executive Vice President of Global Quality at Eli Lilly, Johna Norton, reported the acquisition and disposal of company stock and restricted stock units on February 1, 2024.

Eli Lilly executive Jacob Van Naarden reported the acquisition and disposal of company stock and restricted stock units on February 1, 2024.